Pharmacokinetic and Pharmacodynamic of Jia Shen Tablets in Chronic Heart Failure - Trial NCT06348498
Access comprehensive clinical trial information for NCT06348498 through Pure Global AI's free database. This Phase 1 trial is sponsored by Tasly Pharmaceutical Group Co., Ltd and is currently Not yet recruiting. The study focuses on Heart Failure. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tasly Pharmaceutical Group Co., Ltd
Timeline & Enrollment
Phase 1
Mar 31, 2024
Jun 30, 2026
Primary Outcome
Pharmacokinetic characteristic evaluation๏ผMaximum observed plasma concentration (Cmax),Plasma PK analysis: Time to reach peak or maximum observed concentration following drug administration (Tmax),Plasma PK analysis: Area under curve at steady state (AUCss)
Summary
Evaluate the pharmacokinetic and pharmacodynamic characteristics of Jia Shen Tablets in
 patients with Chronic Heart Failure.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06348498
Non-Device Trial